Hims & Hers Health Inc. (HIMS) plunged over 25% in Tuesday's pre-market session, following the FDA's decision to remove the popular weight loss drugs Wegovy and Ozempic from the shortage list last week.
The telehealth company has been a major beneficiary of selling compounded alternatives to these drugs when they were in short supply. However, with the shortage now resolved, compounding pharmacies that supplied Hims & Hers will be forced to halt production of the knockoffs by May 22nd.
This development has cast doubt on Hims & Hers' ability to sustain the robust growth in its weight loss drug business, which was a key revenue driver. While the company plans to transition to offering oral weight loss solutions and generic liraglutide, analysts remain skeptical about its lofty 2025 sales forecast for the segment, citing concerns over slower adoption of the new offerings.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。